Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic
Despite substantial progress in confronting the global HIV-1 epidemic since its inception in the 1980s, better approaches for both treatment and prevention will be necessary to end the epidemic and remain a top public health priority. Antiretroviral therapy (ART) has been effective in extending lives, but at a cost of lifelong adherence to treatment. Broadly neutralizing antibodies (bNAbs) are directed to conserved regions of the HIV-1 envelope glycoprotein trimer (Env) and can block infection if present at the time of viral exposure. The therapeutic application of bNAbs holds great promise, and progress is being made toward their development for widespread clinical use. Compared to the current standard of care of small molecule-based ART, bNAbs offer: (1) reduced toxicity; (2) the advantages of extended half-lives that would bypass daily dosing requirements; and (3) the potential to incorporate a wider immune response through Fc signaling. Recent advances in discovery technology can enable system-wide mining of the immunoglobulin repertoire and will continue to accelerate isolation of next generation potent bNAbs. Passive transfer studies in pre-clinical models and clinical trials have demonstrated the utility of bNAbs in blocking or limiting transmission and achieving viral suppression.
These studies have helped to define the window of opportunity for optimal intervention to achieve viral clearance, either using bNAbs alone or in combination with ART. None of these advances with bNAbs would be possible without technological advancements and expanding the cohorts of donor participation. Together these elements fueled the remarkable growth in bNAb development. Here, we review the development of bNAbs as therapies for HIV-1, exploring advances in discovery, insights from animal models and early clinical trials, and innovations to optimize their clinical potential through efforts to extend half-life, maximize the contribution of Fc effector functions, preclude escape through multiepitope targeting, and the potential for sustained delivery.
Symptoms, antibody levels and vaccination attitude after asymptomatic to moderate COVID-19 infection in 200 healthcare workers
Aim: In Germany, the willingness to be vaccinated against COVID-19 is rather low among medical staff. We collected data on symptoms, antibody titers and vaccination readiness from clinic employees at a municipal clinic who had already been through a COVID-19 infection (asymptomatic to moderate). We also examined the antibody titers for their possible importance as an individual decision-making aid with regard to vaccination.
Method: 200 employees of our municipal clinics were included in the study. COVID-19 antibody determination was performed using an ELISA (EUROIMMUN™, PerkinElmer, Inc. Company). The participants were given an anonymous questionnaire containing anthropometrical issues, symptoms of the infection and questions concerning the vaccination decision. Finally, the antibody levels were reported to the participants and the attitude towards a vaccination was reevaluated.
Results: In all 200 participants who had already gone through a COVID-19 infection, 75 employees were in favor of a vaccination (37.5%), 96 were opposed to vaccination (48%), and 29 were undecided (14.5%). In the different occupational groups, the positive trend in terms of willingness to be vaccinated was highest among physicians and is least among nurses. The antibody results showed considerable variation in titer levels and therefore did not correlate with disease severity in asymptomatic to moderately ill persons. We also observed a pro-vaccination trend with increasing age of the participants. The specifically-asked symptom of cutaneous hyperesthesia during COVID-19 infection occurred in 5% of the participants.
Conclusion: In medical personnel who had already suffered from a COVID-19 infection, the willingness to receive a vaccination tends to be highest among physicians, and lowest in nurses, and increases with age. For the vast majority of those affected, knowledge of the antibody titers only reinforces the vaccination decision made beforehand and thus does not contribute to a change in vaccination decision. The specifically-requested symptom of cutaneous hyperesthesia during COVID-19 infection was unexpectedly frequent.
Engineering a novel IgG-like bispecific antibody against enterovirus A71
Frequent outbreaks of enterovirus A71 (EVA71) occur in the Asia-Pacific area, and these are closely associated with severe neurological symptoms in young children. No effective antiviral therapy is currently available for the treatment of EVA71 infection. The development of monoclonal antibodies (mAbs) has demonstrated promise as a novel therapy for the prevention and treatment of infectious diseases. Several medical conditions have been treated using bispecific or multi-specific antibodies that recognize two or more distinct epitopes simultaneously. However, bispecific or multi-specific antibodies often encounter protein expression and product stability problems.
In this study, we developed an IgG-like bispecific antibody (E18-F1) comprising two anti-EVA71 antibodies: E18 mAb and llama-derived F1 single-domain antibody. E18-F1 was demonstrated to exhibit superior binding affinity and antiviral activity compared with E18 or F1. Additionally, E18-F1 not only improved survival rate, but also reduced clinical signs in human SCARB2 receptor (hSCARB2) transgenic mice challenged with a lethal dose of EVA71. Altogether, our results reveal that E18-F1 is a simple format bispecific antibody with promising antiviral activity for EVA71.
Myelin Oligodendrocyte Glycoprotein-antibody-associated Disorder Presenting with Corticomeningeal Encephalitis prior to the Onset of Optic Neuritis
We herein report a case of myelin oligodendrocyte glycoprotein-antibody-associated disorder (MOG-AD) presenting with corticomeningeal encephalitis. The patient exhibited oral ulceration, a mild impairment of consciousness, fever, nausea, nuchal rigidity, positivity for human leukocyte antigen type B51, and neutrophil-dominant pleocytosis and interleukin-6 level in cerebrospinal fluid (CSF). Magnetic resonance imaging (MRI) revealed a right temporal lesion with leptomeningeal gadolinium enhancement.
The initial diagnosis was neuro-Behçet’s disease presenting with meningoencephalitis; however, a cell-based assay detected anti-MOG antibody in the serum and CSF and the patient also experienced bilateral optic neuritis. After administering steroid therapy, his neurologic symptoms and CSF abnormalities improved along with the disappearance of gadolinium enhancement and the lesion on MRI. This case suggests that MOG-AD may present with corticomeningeal encephalitis prior to the onset of optic neuritis.
 Anti-VEGF/VEGF164 Antibody |
|||
| A00045-1 | BosterBio | 100ug/vial | EUR 294 |
 Anti-VEGF/Vegfa Antibody |
|||
| A00045-2 | BosterBio | 100ug/vial | EUR 294 |
 Anti-VEGF-C Antibody |
|||
| A00623 | BosterBio | 100ul | EUR 397 |
|
Description: Rabbit Polyclonal Antibody for VEGF-C Antibody (VEGFC) detection.tested for IHC, WB in Human, Mouse, Rat. |
|||
 Anti-VEGF-C antibody |
|||
| STJ96662 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Rabbit polyclonal to VEGF-C. |
|||
 Anti-VEGF-B antibody |
|||
| STJ96851 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Rabbit polyclonal to VEGF-B. |
|||
 anti-VEGF Receptor 1 |
|||
| YF-PA11817 | Abfrontier | 50 ug | EUR 363 |
|
Description: Mouse polyclonal to VEGF Receptor 1 |
|||
anti-VEGF Receptor 1 |
|||
| YF-PA11818 | Abfrontier | 100 ug | EUR 403 |
|
Description: Rabbit polyclonal to VEGF Receptor 1 |
|||
 anti-VEGF Receptor 3 |
|||
| YF-PA23727 | Abfrontier | 50 ul | EUR 334 |
|
Description: Mouse polyclonal to VEGF Receptor 3 |
|||
 Anti-VEGF Antibody Clone VEGF/1063, Unconjugated-100ug |
|||
| 7422-MSM1-P1 | EnQuireBio | 100ug | EUR 428 |
 Polyclonal Goat anti-GST α-form |
|||
| GST-ANTI-1 | Detroit R&D | 50 uL | EUR 280 |
 Polyclonal Goat anti-GST μ-form |
|||
| GST-ANTI-2 | Detroit R&D | 50 uL | EUR 280 |
 Polyclonal Goat anti-GST p-form |
|||
| GST-ANTI-3 | Detroit R&D | 50 uL | EUR 280 |
 Naja mossambica Snake venom metalloproteinase-disintegrin-like mocarhagin |
|||
| 1-CSB-EP606027NAH | Cusabio |
|
|
|
Description: Recombinant Naja mossambica Snake venom metalloproteinase-disintegrin-like mocarhagin expressed in E.coli |
|||
, Peptide Aptamer, FITC labelled) VEGF receptor Flt-1 (F56), Peptide Aptamer, FITC labelled |
|||
| AP-334-F | Alpha Diagnostics | 1 mg | Ask for price |
 anti-Apolipoprotein F |
|||
| YF-PA10244 | Abfrontier | 50 ul | EUR 363 |
|
Description: Mouse polyclonal to Apolipoprotein F |
|||
anti-Apolipoprotein F |
|||
| YF-PA10245 | Abfrontier | 50 ug | EUR 363 |
|
Description: Mouse polyclonal to Apolipoprotein F |
|||
anti-Apolipoprotein F |
|||
| YF-PA10246 | Abfrontier | 100 ug | EUR 403 |
|
Description: Rabbit polyclonal to Apolipoprotein F |
|||
 anti-Cyclophilin F |
|||
| YF-PA25484 | Abfrontier | 50 ul | EUR 334 |
|
Description: Mouse polyclonal to Cyclophilin F |
|||
 anti-Cathepsin F |
|||
| YF-PA15821 | Abfrontier | 50 ul | EUR 363 |
|
Description: Mouse polyclonal to Cathepsin F |
|||
anti-Cathepsin F |
|||
| YF-PA15822 | Abfrontier | 50 ug | EUR 363 |
|
Description: Mouse polyclonal to Cathepsin F |
|||
 Anti-VEGF Rabbit Monoclonal Antibody |
|||
| M00045-1 | BosterBio | 100ug/vial | EUR 397 |
|
Description: Rabbit Monoclonal VEGF Antibody. Validated in Flow Cytometry, IP, IF, IHC, ICC and tested in Human, Mouse. |
|||
 Anti-VEGF-A Humanized Antibody |
|||
| A2136-100 | Biovision | 100 µg | EUR 510 |
, humanized Antibody) Anti-VEGF (Bevacizumab), humanized Antibody |
|||
| A1045-100 | Biovision | EUR 501 | |
) Anti-VEGF Receptor 3 (5B6) |
|||
| YF-MA10355 | Abfrontier | 100 ug | EUR 363 |
|
Description: Mouse monoclonal to VEGF Receptor 3 |
|||
) Anti-VEGF Receptor 3 (5F11) |
|||
| YF-MA13094 | Abfrontier | 100 ug | EUR 363 |
|
Description: Mouse monoclonal to VEGF Receptor 3 |
|||
) Anti-VEGF Receptor 3 (6F9) |
|||
| YF-MA13095 | Abfrontier | 100 ug | EUR 363 |
|
Description: Mouse monoclonal to VEGF Receptor 3 |
|||
) Anti-VEGF Receptor 3 (5B5) |
|||
| YF-MA13096 | Abfrontier | 100 ug | EUR 363 |
|
Description: Mouse monoclonal to VEGF Receptor 3 |
|||
) Anti-VEGF Receptor 3 (4D1) |
|||
| YF-MA13097 | Abfrontier | 100 ug | EUR 363 |
|
Description: Mouse monoclonal to VEGF Receptor 3 |
|||
) Anti-VEGF Receptor 3 (2E3) |
|||
| YF-MA13098 | Abfrontier | 100 ug | EUR 363 |
|
Description: Mouse monoclonal to VEGF Receptor 3 |
|||
) Anti-VEGF Receptor 3 (1C1) |
|||
| YF-MA13099 | Abfrontier | 100 ug | EUR 363 |
|
Description: Mouse monoclonal to VEGF Receptor 3 |
|||
) Anti-VEGF Receptor 3 (6B7) |
|||
| YF-MA13100 | Abfrontier | 100 ug | EUR 363 |
|
Description: Mouse monoclonal to VEGF Receptor 3 |
|||
) Anti-VEGF Receptor 2 (2A2) |
|||
| YF-MA13909 | Abfrontier | 100 ug | EUR 363 |
|
Description: Mouse monoclonal to VEGF Receptor 2 |
|||
) Anti-VEGF Receptor 2 (4A2) |
|||
| YF-MA13910 | Abfrontier | 100 ug | EUR 363 |
|
Description: Mouse monoclonal to VEGF Receptor 2 |
|||
) Anti-VEGF Receptor 2 (2C5) |
|||
| YF-MA13911 | Abfrontier | 100 ug | EUR 363 |
|
Description: Mouse monoclonal to VEGF Receptor 2 |
|||
) Anti-VEGF Receptor 2 (4B5) |
|||
| YF-MA13912 | Abfrontier | 100 ug | EUR 363 |
|
Description: Mouse monoclonal to VEGF Receptor 2 |
|||
) Anti-VEGF Receptor 2 (4F1) |
|||
| YF-MA13913 | Abfrontier | 100 ug | EUR 363 |
|
Description: Mouse monoclonal to VEGF Receptor 2 |
|||
 ELISA Kit) Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
| DLR-EG-VEGF-b-48T | DL Develop | 48T | EUR 493 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma or other biological fluids. |
|||
Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
| DLR-EG-VEGF-b-96T | DL Develop | 96T | EUR 641 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma or other biological fluids. |
|||
 ELISA Kit) Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
| DLR-EG-VEGF-Hu-48T | DL Develop | 48T | EUR 336 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
| DLR-EG-VEGF-Hu-96T | DL Develop | 96T | EUR 425 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
 ELISA Kit) Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
| DLR-EG-VEGF-Mu-48T | DL Develop | 48T | EUR 435 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
| DLR-EG-VEGF-Mu-96T | DL Develop | 96T | EUR 561 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
 ELISA Kit) Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
| DLR-EG-VEGF-Ra-48T | DL Develop | 48T | EUR 454 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
| DLR-EG-VEGF-Ra-96T | DL Develop | 96T | EUR 587 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
| RD-EG-VEGF-b-48Tests | Reddot Biotech | 48 Tests | EUR 494 |
Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
| RD-EG-VEGF-b-96Tests | Reddot Biotech | 96 Tests | EUR 684 |
Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
| RD-EG-VEGF-Hu-48Tests | Reddot Biotech | 48 Tests | EUR 317 |
Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
| RD-EG-VEGF-Hu-96Tests | Reddot Biotech | 96 Tests | EUR 431 |
Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
| RD-EG-VEGF-Mu-48Tests | Reddot Biotech | 48 Tests | EUR 429 |
Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
| RD-EG-VEGF-Mu-96Tests | Reddot Biotech | 96 Tests | EUR 591 |
Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
| RD-EG-VEGF-Ra-48Tests | Reddot Biotech | 48 Tests | EUR 450 |
Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
| RD-EG-VEGF-Ra-96Tests | Reddot Biotech | 96 Tests | EUR 622 |
Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
| RDR-EG-VEGF-b-48Tests | Reddot Biotech | 48 Tests | EUR 516 |
Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
| RDR-EG-VEGF-b-96Tests | Reddot Biotech | 96 Tests | EUR 716 |
Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
| RDR-EG-VEGF-Hu-48Tests | Reddot Biotech | 48 Tests | EUR 330 |
Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
| RDR-EG-VEGF-Hu-96Tests | Reddot Biotech | 96 Tests | EUR 450 |
Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
| RDR-EG-VEGF-Mu-48Tests | Reddot Biotech | 48 Tests | EUR 447 |
Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
| RDR-EG-VEGF-Mu-96Tests | Reddot Biotech | 96 Tests | EUR 618 |
Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
| RDR-EG-VEGF-Ra-48Tests | Reddot Biotech | 48 Tests | EUR 470 |
Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
| RDR-EG-VEGF-Ra-96Tests | Reddot Biotech | 96 Tests | EUR 651 |
 VEGF |
|||
| MO15067 | Neuromics | 500 ug | EUR 910 |
VEGF |
|||
| PR15028 | Neuromics | 10 ug | EUR 461 |
VEGF |
|||
| LF-PR009 | Abfrontier | 10 ug | EUR 255 |
|
Description: VEGF protein |
|||
, Peptide Aptamer, FITC labelled) VEGF receptor KDR/Flk-1 (K237), Peptide Aptamer, FITC labelled |
|||
| AP-336-F | Alpha Diagnostics | 1 mg | Ask for price |
, Peptide Aptamer, FITC labelled) VEGF receptor KDR and Flt-1 (v107), Peptide Aptamer, FITC labelled |
|||
| AP-335-F | Alpha Diagnostics | 1 mg | Ask for price |
 VEGF-stimulated Human Umbilical Vein Endothelial Cell, Peptide Aptamer, FITC labelled |
|||
| AP-338-F | Alpha Diagnostics | 1 mg | Ask for price |
 VEGF-stimulated human umbilical vein endothelial cells, Peptide Aptamer, FITC labelled |
|||
| AP-339-F | Alpha Diagnostics | 1 mg | Ask for price |
 Antibody) VEGF-A(VEGF/1063) Antibody |
|||
| BNCA1063-250 | Biotium | 250uL | EUR 383 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), APC conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNC811063-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNC811063-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNCAP1063-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNCAP1063-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNCB1063-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), Biotin conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNCB1063-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), Biotin conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNC471063-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF647 conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNC471063-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF647 conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNC551063-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNC551063-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNC431063-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNC431063-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNC881063-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF488A conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNC881063-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF488A conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNC941063-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF594 conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNC941063-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF594 conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNCP1063-250 | Biotium | 250uL | EUR 383 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), PerCP conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNC041063-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF405S conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNC041063-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF405S conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNCR1063-250 | Biotium | 250uL | EUR 383 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), RPE conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNUB1063-100 | Biotium | 100uL | EUR 209 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), Concentration: 0.2mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNUB1063-500 | Biotium | 500uL | EUR 458 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), Concentration: 0.2mg/mL |
|||
